Prognosis

FDA Moving at ‘Lightning Speed’ on Gilead Drug, Commissioner Says

Commissioner Hahn says agency wants to see totality of data
Several different pathways available for review, Hahn says

Fauci Says Gilead Data Shows Covid-19 Drug Has 'Clear-Cut' Positive Effect

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Anna Edney

April 30, 2020 at 1:17 PM UTC

Updated on

April 30, 2020 at 2:32 PM UTC

This article is for subscribers only.

Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.

The Food and Drug Administration is moving at “lightning speed” to review data on Gilead Sciences Inc.’s experimental Covid-19 treatment remdesivir, Commissioner Stephen Hahn said, after encouraging results emerged from a key U.S. trial.